Avidity Partners 13F holdings, Q3 2020
Holdings as of September 30, 2020 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 66 US equity positions worth $1.9bn in its Q3 2020 13F filing. The largest position was ABBV at 7.2% of the reported book, followed by SEATTLE GENETICS INC and AVTR. Against the Q2 2020 filing, it opened 27 new positions, added to 15 and reduced 8 among the top 50 holdings.
What did Avidity Partners own in Q3 2020? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2020 |
|---|---|---|---|---|---|---|---|
| 1 | ABBV ABBVIE INC | Healthcare | 7.2% | $133.4m | 1,522,800 | -1% | reduced |
| 2 | SEATTLE GENETICS INC | 5.6% | $103.9m | 531,100 | 112% | added | |
| 3 | AVTR AVANTOR INC | Healthcare | 5.5% | $102.6m | 4,562,400 | 183% | added |
| 4 | MRK MERCK & CO. INC | Healthcare | 5.1% | $94.9m | 1,144,300 | – | new |
| 5 | BIIB BIOGEN INC | Healthcare | 4.8% | $89.4m | 315,100 | – | new |
| 6 | BIOHAVEN PHARMACTL HLDG CO L | 4.5% | $83.5m | 1,284,200 | 16% | added | |
| 7 | HORIZON THERAPEUTICS PUB L | 3.9% | $72.3m | 930,200 | 73% | added | |
| 8 | NBP I MAB | Healthcare | 3.4% | $63.0m | 1,340,000 | – | new |
| 9 | AUPH AURINIA PHARMACEUTICALS INC | Healthcare | 2.8% | $52.5m | 3,564,900 | 44% | added |
| 10 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 2.8% | $52.2m | 118,300 | – | new |
| 11 | BRISTOL-MYERS SQUIBB CO | 2.7% | $51.0m | 22,684,932 | 292% | added | |
| 12 | BAX BAXTER INTL INC | Healthcare | 2.7% | $49.9m | 620,000 | -23% | reduced |
| 13 | ELV ANTHEM INC | Healthcare | 2.6% | $47.4m | 176,400 | – | new |
| 14 | DGX QUEST DIAGNOSTICS INC | Healthcare | 2.5% | $46.0m | 402,000 | – | new |
| 15 | MIRATI THERAPEUTICS INC | 2.5% | $45.7m | 275,000 | – | new | |
| 16 | QUIDEL CORP | 2.1% | $38.8m | 176,879 | – | new | |
| 17 | BSX BOSTON SCIENTIFIC CORPORATION | Healthcare | 2.0% | $37.0m | 967,100 | – | new |
| 18 | CHANGE HEALTHCARE INC | 2.0% | $36.7m | 2,527,500 | – | new | |
| 19 | NTRA NATERA INC | Healthcare | 2.0% | $36.4m | 503,400 | – | new |
| 20 | KDMN KADMON HLDGS INC | 1.9% | $35.4m | 9,030,000 | 41% | added | |
| 21 | ARVN ARVINAS INC | Healthcare | 1.7% | $31.8m | 1,348,300 | 25% | added |
| 22 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 1.6% | $29.6m | 904,119 | 34% | added |
| 23 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.5% | $27.4m | 1,854,100 | 21% | added |
| 24 | CATALENT INC | 1.5% | $27.2m | 318,100 | – | new | |
| 25 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 1.4% | $26.3m | 799,000 | 8% | added |
| 26 | TRILLIUM THERAPEUTICS INC | 1.3% | $24.8m | 1,746,000 | – | new | |
| 27 | BTAI BIOXCEL THERAPEUTICS INC | 1.3% | $23.3m | 538,000 | 39% | added | |
| 28 | HUM HUMANA INC | Healthcare | 1.1% | $21.3m | 51,500 | – | new |
| 29 | ANIK ANIKA THERAPEUTICS INC | Healthcare | 1.1% | $21.3m | 601,700 | 66% | added |
| 30 | COLL COLLEGIUM PHARMACEUTICAL INC | Healthcare | 1.1% | $20.8m | 1,000,400 | – | new |
| 31 | HARPOON THERAPEUTICS INC | 1.1% | $19.9m | 1,171,700 | -3% | reduced | |
| 32 | AMARIN CORP PLC | 1.0% | $19.0m | 4,506,000 | – | new | |
| 33 | ATHIRA PHARMA INC | 1.0% | $18.9m | 1,026,342 | – | new | |
| 34 | MDT MEDTRONIC PLC | Healthcare | 1.0% | $18.8m | 181,000 | 4% | added |
| 35 | EXEL EXELIXIS INC | Healthcare | 1.0% | $18.8m | 769,200 | -71% | reduced |
| 36 | APELLIS PHARMACEUTICALS INC | 1.0% | $18.8m | 623,300 | – | new | |
| 37 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 1.0% | $18.4m | 7,324,000 | – | new |
| 38 | ADAPY ADAPTIMMUNE THERAPEUTICS PLS | Healthcare | 0.9% | $16.6m | 2,084,700 | 45% | added |
| 39 | ESSA PHARMA INC | 0.8% | $14.4m | 2,087,800 | – | new | |
| 40 | BNTX BIONTECH SE | Healthcare | 0.8% | $14.3m | 206,000 | – | new |
| 41 | MERSANA THERAPEUTICS INC | 0.8% | $14.1m | 757,400 | -29% | reduced | |
| 42 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.7% | $13.2m | 1,050,800 | -21% | reduced |
| 43 | ZYME ZYMEWORKS INC | Healthcare | 0.6% | $11.4m | 244,700 | – | new |
| 44 | ALDX ALDEYRA THERAPEUTICS INC | Healthcare | 0.6% | $10.6m | 1,430,000 | – | new |
| 45 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.5% | $8.8m | 392,000 | – | new |
| 46 | DVAX DYNAVAX TECHNOLOGIES CORP | 0.5% | $8.7m | 2,025,000 | -24% | reduced | |
| 47 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 0.5% | $8.4m | 118,000 | -71% | reduced |
| 48 | ITEOS THERAPEUTICS INC | 0.4% | $8.1m | 330,000 | – | new | |
| 49 | ACIU AC IMMUNE SA | Healthcare | 0.4% | $7.6m | 1,550,000 | – | new |
| 50 | ALPINE IMMUNE SCIENCES INC | 0.4% | $7.1m | 810,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.